An innovative nanozyme-based aptasensor detects interleukin-18, suggesting a reliable method for biomarker detection.
By synthesizing a bimetallic iron and nickel organic framework (FeNi-MOF) hybrid as the nanozyme, herein we developed an innovative voltammetric ‘off–on’ aptasensor platform of interleukin-18 (IL-18) for the first-time. This nanozyme catalyzes the conversion of 1,2-diaminobenzene to diaminophenazinc (DAP), an electroactive substance. However, upon binding to the aptamer (Apt) sensing of IL-18, its enzyme-like activity is inhibited as the active sites are obscured by the Apt, leading to the disappearance of DAP current (signal ‘off’). Interestingly, in the presence of IL-18, the activity is restored because specific binding between the Apt and IL-18 displaces the Apt from the FeNi-MOF surface, resulting in an increase in DAP current (signal ‘on’). After optimizing key conditions, this ‘off-on’ nanozyme-based electrochemical aptasensor demonstrates excellent detection performance for IL-18 and provides a novel, simple, and reliable strategy for detecting various biomarkers by simply altering the relative Apt.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: